|
Alopecia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fibroblast Growth Factor (FGF) signaling is important in this developmental pathway, as deletion of FGF receptor 1 (Fgfr1) or its ligand, Fgf20, leads to the loss of hair cells and supporting cells from the organ of Corti.
|
31276493 |
2019 |
|
Depressive Symptoms
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
A statistically significant association of the functional polymorphism in the FGF20 gene (rs12720208) with depressive symptoms was found.
|
30241547 |
2018 |
|
Parkinsonian Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Our study is the first to uncover the potential link between manganese exposure, altered miRNA expression and parkinsonism: manganese exposure causes overexpression of SNCA and FGF-20 by diminishing miR-7 and miR-433 levels.
|
28986288 |
2018 |
|
Class III malocclusion
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We also identified 3 variants: rs13317 in FGFR1, rs149242678 in FGF20, and rs79176051 FGF12 associated with MP (P < .05).
|
28640125 |
2017 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Ectodysplasin target gene Fgf20 regulates mammary bud growth and ductal invasion and branching during puberty.
|
28698625 |
2017 |
|
Essential Tremor
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The findings indicate the FGF20 gene might not play a dominating role in the genetic predisposition to ET in Chinese Han population.
|
27040428 |
2016 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Four of these validated variants were nonsense mutations, six were observed in genes directly or indirectly related to neurodegenerative disorders (NDs), such as LPA, LRRK2, and FGF20.
|
27341347 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings show that: (I) HNF4 is a common potential transcription factor mediating the transcription of NAFLD progression genes (II) mice HCC derived from NAFLD co-cluster with a less aggressive human HCC subtype of differential prognosis and mixed etiology (III) the HCC survival signature is able to correctly classify 95% of the samples and gives Fgf20 and Tgfb1i1 as the most robust genes for prediction (IV) the expression values of genes composing the signature in an independent human HCC dataset revealed different HCC subtypes showing differences in survival time by a Logrank test.
|
25993042 |
2015 |
|
Sporadic Parkinson disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Fibroblast growth factor 20 polymorphism in sporadic Parkinson's disease in Northern Han Chinese.
|
23938014 |
2013 |
|
Ataxia, Spinocerebellar
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
|
19621416 |
2009 |
|
Hypophosphatemic Rickets
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
|
19621416 |
2009 |
|
Familial Hypophosphatemic Rickets
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
|
19621416 |
2009 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Finally, by using small inhibitory RNAs specific for FGF20, we show that continued expression of FGF20 is necessary for maintenance of the anchorage-independent growth state in RK3E cells transformed by beta-catenin, implying that FGF-20 may be a critical element in oncogenesis induced by the Wnt signaling pathway.
|
15592430 |
2005 |
|
Inflammatory Bowel Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
FGF-20, having demonstrated therapeutic activity in 2 experimental models of intestinal inflammation, represents a promising new candidate for the treatment of human inflammatory bowel disease.
|
12360478 |
2002 |
|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FGF-20 mRNA of 2.4 kb in size was detected in colon cancer cell line SW480 by Northern blot analysis.
|
10913340 |
2000 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FGF-20 mRNA of 2.4 kb in size was detected in colon cancer cell line SW480 by Northern blot analysis.
|
10913340 |
2000 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.
|
28921304 |
2017 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings show that: (I) HNF4 is a common potential transcription factor mediating the transcription of NAFLD progression genes (II) mice HCC derived from NAFLD co-cluster with a less aggressive human HCC subtype of differential prognosis and mixed etiology (III) the HCC survival signature is able to correctly classify 95% of the samples and gives Fgf20 and Tgfb1i1 as the most robust genes for prediction (IV) the expression values of genes composing the signature in an independent human HCC dataset revealed different HCC subtypes showing differences in survival time by a Logrank test.
|
25993042 |
2015 |
|
Colorectal Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The level of Dickkopf-4 was positively correlated with fibroblast growth factor-20 (r(s) = 0.61, P = 0.00017), a representative beta-catenin transcriptional target gene, and with the degree of nuclear accumulation of beta-catenin in colorectal tumors.
|
19659606 |
2009 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development.
|
15592430 |
2005 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development.
|
15592430 |
2005 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
These results underscore the utility of mining genomic DNA databases and reveal FGF-20 to be a novel oncogene that may play a role in human cancer.
|
11306498 |
2001 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
These results underscore the utility of mining genomic DNA databases and reveal FGF-20 to be a novel oncogene that may play a role in human cancer.
|
11306498 |
2001 |
|
Colorectal Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Molecular cloning and characterization of human FGF-20 on chromosome 8p21.3-p22.
|
10913340 |
2000 |
|
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In silico interrogation of the Broad Institute's Connectivity Map database (CMap), revealed 50 candidate drugs predicted to increase FGF20 transcription, 16 of which had profiles favourable for use in Parkinson's disease.
|
31171821 |
2019 |